Toronto, Ontario–(Newsfile Corp. – October 14, 2021) – Glow LifeTech Corp. (CSE: GLOW) (OTCQB: GLWLF) (FSE: 9DO) (“Glow” or the “Company“) is pleased to provide an update on new appointments to support the Company’s advancing manufacturing and commercial initiatives including the appointment of Josh Bald, CPA as Glow’s dedicated CFO.

As with many industries, Glow’s setup of manufacturing and production related operations have been delayed due to supply shortages stemming from the COVID-19 pandemic. The Company now anticipates that these delays are coming to an end and in turn has accelerated the expansion of its product development and manufacturing team with the appointment of Brian Dymond as Director of Manufacturing and Petro Czupiel, Ph.D as Lead Product Development Scientist.

“We are thrilled to welcome Petro and Brian to the team, and confident in their leadership and contributions to the advancement of our disruptive product lines,” said W. Clark Kent, CEO of Glow LifeTech Corp.

Petro Czupiel, Ph.D
Lead Product Development Scientist

Petro obtained his Ph.D from University of Toronto at the Department of Chemical Engineering in collaboration with the Institute of Biomaterials and Biomedical Engineering. Petro has worked on and published scientific articles related to various microemulsion and nanoemulsion components and systems during his graduate studies. Petro has a breadth of formulation science experience, developing nanoemulsions of nutraceuticals and nutrient compounds. He was formerly a formulation scientist at a top 5 Canadian cannabis extraction company and advanced product formulations from concept to product, including stability programs, taste, testing, validation, and scale-up of production processes. Petro led the design of rapid-acting cannabis beverages, water-soluble cannabis extracts, advanced edibles, and topical creams. He was formerly the Chief Science Officer at Next Remedies located in Toronto. Petro’s experience and expertise in formulation will be of tremendous value to executing Glow’s product development strategy.

Brian Dymond
Director of Manufacturing

Mr. Dymond has over 20 years of facility engineering experience with international Pharmaceutical companies, formerly working with Apotex Inc.¹, Canada’s largest generic drug manufacturer². Brian now specializes in technical and manufacturing consulting within the pharma, food and cannabis industries. Brian has decades of experience in full-scale capital expansions and leasehold improvement projects, including leading a green field expansion of a $26M CAD antibiotic production facility, managing the conceptual design to the validation and commencement of commercial operations. Brian has consulted numerous cannabis facilities on EU-GMP regulations and proper facility design, most recently at Northern Green Canada Inc.³. Brian has a degree in engineering and a secondary degree in business management. Brian has also managed many organizational improvement projects to support cost effectiveness, sustainability and process optimization. Brian has previously worked for global companies such as the french multinational firm, Sanofi Pasteur, where he managed a $45 million expansion of the Pertussis vaccine production facility.⁴ Brain currently leads Glow’s technical build-out and manages its full-scale capital expansions and leasehold improvement projects. Brian primarily focuses on process optimization, cost effectiveness and sustainability for Glow’s manufacturing, facilities and operations.

Glow Appoints Josh Bald as Dedicated CFO

Josh Bald, CPA
CFO

Josh has held senior accounting positions at Ernst and Young⁵, in the audit assurance sector. Prior to his leadership roles at EY, he obtained an Honours Business Administration degree from Richard Ivey School of Business at Western University, and further to that obtained his Chartered Professional Accountant designation. Josh has international public company and capital markets experience having worked with multiple issuers, and leading financial strategy, growth and corporate compliance which will be a key addition to Glow.

Chris Hopkins has been the CFO of Glow from its inception in 2018, and the Company gives thanks to Chris as a crucial person in the efforts to advance Glow in early stages and oversee its public listing. Chris will continue to advise the Company on strategic initiatives.

Glow LifeTech Management and Directors

W. Clark Kent
CEO & Director

Mr. Kent is a capital markets professional with extensive experience leading corporate development and finance initiatives in the natural resources, technology and life science sectors. For over a decade he has advised emerging companies on strategic planning, finance and recruitment in the North American and international marketplace.

Tom Glawdel, Ph.D
COO

Tom obtained a Ph.D in Mechanical and Mechatronics Engineering from Waterloo in 2012. Mr. Glawdel has 10 years of experience leading high-performing research and development teams in biotechnology and medical technology and is acting Chief Scientific Officer for Relay Medical. He has in-depth knowledge in medical diagnostic development, microfluidics, nanomaterials and a broad experience in building early stage technologies. Previously, he was the director of Product Development and Engineering for a start-up medical device company, 3RCardio, and was Assistant Director of R&D for Xagenic managing cross-functional teams developing a cutting edge molecular diagnostic product. Mr. Glawdel has extensive experience working in a regulated environment developing products requiring Health Canada and FDA approval processes. Tom provides a wide range of valuable skills to Glow and currently leads the operations and technical development projects within the Company.

Rob Carducci
CCO & Director

Mr. Carducci formerly worked at Nestle⁶ and Kraft Foods⁷, leading several global brands and their commercial strategy. Most recently Rob served as Marketing Director for the largest cannabis information website in the world, Leafly.com⁸, which sees roughly 120 million annual website visitors⁹. Mr. Carducci graduated with an HBA at Ivey Business School in 2009 and is a seasoned marketing executive with over a decade of leadership experience building iconic global brands including Delissio, Drumstick, Smarties and KitKat. As CCO, Roberto is responsible for building Glow’s commercialization strategy and infrastructure to drive market adoption for its technology and product portfolio across North America. Robert provides strategic leadership for defining the commercial path to growth and profitability, and leads the Company’s marketing, sales & business development strategy.

Chris Irwin
Board Member

Chris practices securities and corporate law and has been the President of Irwin Professional Corporation since August, 2006. He advises a number of public companies on a variety of issues including continuous disclosure and regulatory issues, reverse-takeover transactions, initial public offerings and takeover bids. Mr. Irwin also advises boards of directors, including independent committees. Mr. Irwin is a director and/or officer of several public companies and has served as a member of the independent committees for both Trelawney Mining and Exploration Inc. and Seafield Resources. Mr. Irwin obtained an LL.M. from Osgoode Hall Law School in 2009, a LL.B. from the University of New Brunswick in 1994 and a B.A. from Bishop’s University in 1990.

Greg Falck
Board Member

Greg has a diverse leadership background within both the military and private sector. He served nine years as an Electrical and Mechanical Engineering Officer in the Canadian Armed Forces, including two years as a platoon commander in the Canadian Special Operations Regiment responsible for support of the unit’s equipment during all foreign and domestic activities. He also led the development and procurement of a variety of leading-edge military equipment alongside special forces operators, technicians, and industry experts. As head of research and development at Aluula Composites Ltd, Greg and his multidisciplinary team of chemists, engineers, and technologists developed a novel lightweight and ultra high strength composite polymer fabric for commercialization. Their first composite fabric on the market won the ISPO Textrends 2020 Best Product award. Greg graduated from the University of Western Ontario with a Bachelor of Engineering Science in 2009.

Medhanie Tekeste
Board Member

Mr. Tekeste is currently the CIO of Apotex¹⁰, Canada’s largest generic drug manufacturer. Medhanie has over 20 years of information systems experience including many years of broad based management expertise in systems development, implementation and support. He is experienced in strategically and cost-effectively utilizing technology to achieve corporate goals. He has extensive global experience in service delivery in the pharmaceutical industry including Quality, Manufacturing and R&D processes. Medhanie also has considerable experience in laboratory quality assurance testing and computer systems validation. Mr. Tekeste graduated from the University of Toronto with a Bachelor of Science degree in Biochemistry in 1987. Later he graduated Pharmaceutical Technology at Seneca College 1998. Lastly, he obtained a diploma in Information Technology from DeVry Technology Institute in 1994. Medhanie advises and oversees key strategic growth opportunities at Glow, and will continue to be a key asset to the Company.

James Van Staveren
Corporate Development

Mr. Van Staveren graduated from Western University in 2014 and has several years of experience in marketing and corporate finance in public company environments. James manages investor relations and supports corporate development initiatives for Glow.

For the full bio’s of management, please visit the company’s website: www.glowlifetech.com

The Company announces that it has granted an aggregate of 500,000 options to purchase Common Shares of the Company at $0.25 and expiring five years from the date of grant, to certain officers, directors and consultants of the Company.

SUBSCRIBE: For more information on Glow or to subscribe to the Company’s mail list visit: https://www.glowlifetech.com/news

About Glow LifeTech Corp.
Glow LifeTech is a Canadian-based biotechnology company focused on producing nutraceutical and cannabinoid-based products with dramatically enhanced bioavailability, absorption and effectiveness. Glow has rights to the groundbreaking, plant-based MyCell Technology® delivery system, which transforms poorly absorbed natural compounds into enhanced water-compatible concentrates that unlock the full healing potential of the valuable compounds.

Website: www.glowlifetech.com

Contact:
James Van Staveren
Glow LifeTech Corp.
Office. 647-872-9982 ext. 2
TF. 1-844-247-6633 ext. 2
ir@glowlifetech.com

Forward-looking Information Cautionary Statement

Except for statements of historic fact, this news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control. There are no assurances that the commercialization plans for the technology described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which filings are available at www.sedar.com.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

TORONTO, June 23, 2021 (GLOBE NEWSWIRE) — RYAH Group, Inc. (CSE:RYAH) (“RYAH” or the “Company”) today announces that it has completed an initial shipment of its proprietary RYAH Smart Dry Herb Inhalers for use in a pilot study to be conducted by Medicann in Jersey, the largest of the Channel Islands, located between England and France. Medicann is a premier cannabis-specialized clinic, providing patients with access to local specialist doctors and pharmacists that have experience prescribing cannabis-based medication. Medicann is launching an observational study using RYAH Smart Dry Herb Inhalers in order to collect patient feedback on consumption of cannabis strains available on the Island, including strains supplied by Aurora Europe, a subsidiary of Canadian-headquartered Aurora Cannabis Inc., a global leader in the cannabis industry serving both medical and consumer markets and dedicated to helping people improve their lives.

In addition to the pilot program, the parties are working toward an exclusive, definitive supply and distribution agreement, which, if entered into, is expected to position Medicann as the sole supplier and distributor of the RYAH Smart Dry Herb Inhalers in the region.

Jersey, Channel Islands, which is known to have one of the highest GDP per capita in the world, is a British dependency island ideally situated in the English Channel off the coast of France. In 2019, the island’s economy grew by 2.1% in real terms to £4.97 billion.

By 2024, the medicinal cannabis market within the United Kingdom is predicted to be worth nearly US$1.3 billion, servicing nearly 340,000 active patients. According to a report by the United Nations International Narcotics Control Board, the U.K. has emerged as the largest supplier of medicinal cannabis in the world. The European cannabis market is forecast to grow with a compound annual growth rate (CAGR) of 67.4% to reach 3.2 billion euros ($3.75 billion) by 2025.

“We are excited to be initiating our pilot program with Medicann in Jersey, which represents a unique, ‘ring-fenced’ environment for establishing potentially numerous studies on the efficacy of treatments using plant-based therapies. RYAH is pleased to contribute RYAH’s IoT devices and data platform and work with Medicann toward perfecting prescribing practices and dosing regimens,” said Gregory Wagner, CEO of RYAH Group, Inc.

About RYAH Group, Inc.

RYAH Group, Inc. (“RYAH”) is a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry. Its robust artificial intelligence platform aggregates and correlates HIPAA-compliant patient data, which is intended to help doctors and patients personalize plant-based treatments to better predict treatment outcomes. The data collection is relevant for clinics, doctors, dispensaries and pharmaceutical companies and licensed processors (LPs) to monitor and manage formulation effects on patients and demographics. With a strong IP portfolio, RYAH gathers deep and insightful data on the complete patient session and formulation life cycle.

Forward-Looking Statements

This press release contains certain forward-looking information and forward-looking statements within the meaning of applicable securities legislation (collectively “forward-looking statements“). All statements contained in this press release that are not statements of historical fact should be considered forward-looking statements. Forward looking statements are often identified by terms such as “may,” “should,” “anticipate,” “expect,” “potential,” “believe,” “intend” or the negative of these terms and similar expressions. Specifically, forward-looking statements in this press release include, but are not limited to, statements related to (i) the pilot study to be conducted by Medicann in Jersey using RYAH Smart Dry Herb Inhalers; (ii) the Company and Medicann’s efforts to negotiate and enter into an exclusive definitive supply and distribution agreement to position Medicann as the sole supplier and distributor of the RYAH Smart Dry Herb Inhalers in Jersey; and (iii) the anticipated size and growth of the recreational and/or medicinal cannabis market within the United Kingdom and Europe. Forward-looking statements reflect the Company’s current views and intentions with respect to future events based on current information available to the Company and are necessarily subject to certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with or inherent in (i) the general business and economic conditions in the regions in which the Company operates; (ii) the expected benefits of the Company’s product offerings and the anticipated results and experience of users thereof; (iii) the Company’s ability to execute on key priorities, implement business strategies and/or pursue business opportunities; (iv) disruptions in or attacks (including cyberattacks) on the Company’s information technology, internet, network access or other voice or data communications systems or services; (v) changes to, or the application of, laws and regulations; and (vi) such other factors set out in the Company’s public disclosure documents available under the Company’s profile on SEDAR at www.sedar.com. Readers are further cautioned that the assumptions used in the preparation of such forward-looking statements (including, but not limited to, the assumption that (i) the Company will be able to execute on its business plan and will obtain and maintain all necessary permits and authorizations to execute on its business plan; (ii) the Company’s financial condition and development plans do not change as a result of unforeseen events; (iii) there will continue to be a demand, and market opportunity, for the Company’s product offerings; (iv) the Company will be able to establish, preserve and develop its brand and attract and retain required personnel; (v) current and future economic conditions will neither affect the business and operations of the Company nor the Company’s ability to capitalize on anticipated business opportunities; (vi) Medicann will undertake and complete the pilot study in Jersey upon the terms anticipated by the Company; (vii) there will continue to be a viable business opportunity for Medicann and the Company to work together; and (viii) the Company will be able to secure capital and financing on acceptable terms), although considered reasonable by management of the Company at the time of preparation, may prove to be imprecise and result in actual results differing materially from those anticipated, and, as such, undue reliance should not be placed on forward-looking statements. Should any such risk factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Accordingly, readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur.

The forward-looking statements included in this press release are made as of the date of this press release, and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws. All forward-looking statements contained in this press release are expressly qualified by this cautionary statement.

This press release includes market and industry data that has been obtained from third-party sources, including industry publications. The Company believes that the industry data is accurate and that its estimates and assumptions are reasonable, but there can be no assurance as to the accuracy or completeness of this data. Third-party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance as to the accuracy or completeness of included information. Although the data is believed to be reliable, the Company has not independently verified any of the data from third-party sources referred to in this press release or ascertained the underlying economic assumptions relied upon by such sources.

Neither the Canadian Securities Exchange (“CSE”) nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

For additional information, please contact:

Sofiya Kleshchuk
Client Relations
+1 917 210 0543
[email protected]

Gregory Wagner, CEO
+1 917 210 0543
[email protected]

Corporate Communications:
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Cannabidiol, better known as CBD, has become one of the most popular wellness products in the United States over the past couple of years. BDS Analytics and Arcview Market Research expect CBD sales to grow at a 49% compound annual growth rate to surpass $20 billion by 2024—making up about half of the total cannabinoid industry—as sales shift from cannabis dispensaries to pharmacy and grocery stores.

CaniBrands brings extensive consumer packaged goods and branding experience to the CBD space, where it has developed a science-based product line encompassing numerous form factors and proprietary formulations. The company’s Can-i products are supported by 12-time Olympic medalist Dara Torres—its Global Spokesperson—and acclaimed high-performance trainer, Andy O’Brien—its Sports Science Advisor.

In a recent interview with CFN Media, Co-Founder and CEO Chris Lords discusses the company’s unique approach to the market and growing product line:

Are you an accredited investor? Learn how to invest in CaniBrands before it goes public

Holistic Approach with Many Choices

CaniBrands offers a premium product line that includes Can-i Boost, Can-i Sleep, Can-i Mend and Can-i Fresh, which are scientifically-formulated to deliver specific wellness benefits.

The company’s best-seller by revenue, Can-i Boost, combines hemp-derived CBD with a powerful blend of vitamins and herbal extracts designed to keep you alert, energized and clear-headed without any crashes or jitters. Meanwhile, the company’s best-seller by volume, Can-i Sleep, combines the same hemp-derived CBD with melatonin and other supplements designed to promote a healthy sleep cycle.

In addition to these best-selling products, the company’s Can-i Mend addresses pain, inflammation and soreness by accelerating the body’s healing process. The product is popular among athletes looking to cut recovery time and reduce post-workout soreness. And finally, the company’s Can-i Fresh is designed to deliver antioxidants, support the immune system and promote mental clarity on a day-to-day basis.

These products are available in multiple form factors, including a sublingual tincture, oral spray and cream, providing customers with many different choices. For example, many athletes appreciate creams to provide localized pain relief, whereas oral sprays provide a convenient on-the-go form factor for busy people. All of these products can be helpful at different times of the day from Can-i Boost in the morning to Can-i Sleep at night.

Are you an accredited investor? Learn how to invest in CaniBrands before it goes public 

Active Expansion into New Markets

CaniBrands has been actively focused on establishing new distribution channels, expanding into new markets and launch new product lines.

The company began by building their own direct-to-consumer platform before moving onto Amazon Prime to access more households. Pilot programs are exploring the possibility of home delivery reselling in local markets, as well as online affiliate marketing, which could significantly expand its distribution and reach new customers throughout the United States that may not otherwise find them online.

Early next year, the company plans to launch its products in Canada before expanding into other international markets. The company’s Brand Ambassador, former NHL player and media personality Paul Bissonnette, will be integral in supporting the Canadian launch. Since becoming the first country to legalize recreational cannabis, Canada has been widely considered a leading market for cannabinoid-based products.

The company also aims to launch a variety of new product lines over time. For example, the company is exploring softgels, beverage, and other product formats (e.g. topicals, bars, and powders), as well as products containing other cannabinoids (e.g. CBN or CBG). The company’s CaniBuy ecommerce management platform also aims to integrate websites, ecommerce, payments and fulfillment into a single client-facing portal.

Gearing Up to Go Public in the Near-term

CaniBrands recently began a $5 million capital raise targeting accredited investors, and the founders and two strategic investors have already committed more than $1 million of the funding round. Management says that the proceeds will be put towards a variety of revenue-driving activities, as well as R&D and general operational expenses.

With no long-term debt, a seasoned management team, commercial products and a solid business model, the company is well-positioned to capitalize on the rapid growth of the CBD market over the coming years.

Accredited investors that are interested in participating in the funding round are encouraged to sign up to receive an investor presentation and corporate updates.

Are you an accredited investor? Learn how to invest in CaniBrands before it goes public

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://www.cannabisfn.com (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies.  We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

The Yield Growth Corp. (CSE: BOSS) (OTCQB: BOSQF) (Frankfurt: YG3) is a company dedicated to disrupting the health and wellness industry, with its many subsidiaries offering both CBD and THC infused products. By targeting specific niches of the cannabis industry, the company has seen great success both in the US and Canada. Now they turn their focus to aggressively targeting the European market.

Entering the Industry Early on

The European cannabis market is still in its infancy. The availability of cannabis-based products is limited, as is consumer awareness, and this offers enormous opportunity for developed brands to enter and dominate this industry.

Brightfield Group, a leading market intelligence firm for the cannabis industry, has estimated in their recent report that the European CBD market will see incredible growth over the next four years. In 2018 the market was estimated to be at US $318 million, and is expected to grow 400 percent through 2023.

Click here to receive an investor deck and corporate updates

This is an ideal market for the Yield Growth to target. Using their success in the US and Canada as a blueprint, they anticipate that the European market will offer them opportunity for serious growth. ‘We intend to generate significant sales revenue by aligning ourselves with different distributors that have strong networks in diverse regions,’ said Penny Green, CEO of Yield Growth.

Definitive Agreement Announced

Never one to delay, Yield Growth announced on July 10 that they have entered into a definitive agreement with Melorganics Hellas for distribution of Urban Juve products in Greece and Cyprus.

Melorganics Hellas intends to enter the Greek and Cypriot markets with a full line of CBD products. With their plan to building strategic alliances with companies that focus on the development of unique health products that utilise cannabis and botanical oils, they are the ideal candidate to distribute Urban Juve’s Ayurvedic products.

Melorganics will act as the exclusive distributor and non-exclusive e-commerce distributor for Urban Juve products. Per the agreement, the must purchase a minimum amount of Urban Juve products of US $300,000 in the first year and $500,000 in the following years to maintain exclusivity.

This agreement will ensure Yield Growth has significant presence in this market, which marks them as a key contender in the European cannabis industry. Greece legalised cannabis for medical reasons in 2018, and has since enjoyed an upsurge of foreign and local investment.

Urban Juve recently announced it had received a Compliance Certificate for sale of its first product in the European Union, and has plans to register an additional ten products in upcoming months.

Marketing efforts in Europe will begin in the fall, and will include a product feature in the September issue of British Vogue.

Click here to receive an investor deck and corporate updates

Negotiations Underway with Other Distributors

Not one to move slowly, Yield Growth is already in negotiations with distributors for France, Poland, Turkey and the United Kingdom, the latter of which is the largest CBD market in the EU, with projections that it will grow to GB £16.5 billion in the next decade. There are also upcoming meetings set to discuss expansion in South America, Germany and Portugal.

Positioned for Global Success

Yield Growth has proved itself as a dominant business within the crossover market of cannabis products and the wellness industry. Its early success in the US and Canada have marked it as an established brand. With its quick response to developing legislation in the European Union, it has positioned itself to be a leading company as laws in the EU allow the legal cannabis industry to grow. Between its success in North American and its strong alliances with European distributors, Yield Growth has put the wheels in motion to achieve global success.

Click here to receive an investor deck and corporate updates

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

UPDATE ON CASH POSITION

The Company received warrant and stock options exercises during the first quarter of 2019 for total proceeds in excess of $3.7 million.  As at February 28, 2019, the Company had a cash balance of approximately $3.7 million.

FINANCIAL PERFORMANCE

The Company realized revenue of $3,055,442 for the twelve months ended November 30, 2018 as compared to nil for the prior year.  The revenue included consulting revenue of $1,098,364 under Thrive Activations Inc. (“Thrive”) and licensing revenue of $1,957,078 under Urban Juve Provisions Inc. (“Urban Juve”) for manufacturing and distribution rights licensed to third parties for the Canadian, US and certain European markets.

The Company incurred net loss of $9,708,037 for the twelve months ended November 30, 2018 as compared to $1,229,685 for the prior year.  However, many of the expenses incurred in 2018 were one-time and non-recurring expenses or were non-cash expenses not affecting cash flow.  The adjusted earnings before interest, taxes, depreciation and amortization, excluding certain non-operating amounts as shown below (the “Adjusted EBITDA”) was negative $2,504,577 for the twelve months ended November 30, 2018.

The increase in loss was primarily driven by increased stock-based compensation for stock options granted to directors, officers, employees, consultants, and advisors, and consulting fees and wages for development activities and to build up internal capacity to launch Urban Juve and other product lines.

The Company was at the final stage of its initial public offering as at November 30, 2018 and incurred material amount of expenses during the year in professional fees, share-based compensation, office expenses, and other fees that are one-time and non-recurring in nature.  The Company also incurred loss from investments in joint venture of $2,367,766 and loss from termination and amendment of licensing agreements of $1,447,572, and neither of these losses are expected to occur in the future.    

Selected information for the years ended November 30, 2018 and 2017

Adjusted EBITDA for the years ended November 30, 2018 and 2017

Adjusted EBITDA, a measure used by management to indicate operating performance, is defined as earnings before interest, taxes, depreciation and amortization, excluding certain non-operating amounts as shown below. Adjusted EBITDA is not a recognized term under IFRS and is not intended to be an alternative either to gross profit or income before taxes as a measure of operating performance or to cash flows from operating activities as a measure of liquidity.  Additionally, Adjusted EBITDA is not intended to be a measure of free cash flow available for discretionary use, as it does not consider certain cash requirements such as interest payments, tax payments and debt service requirements. The Company uses Adjusted EBITDA to supplement IFRS results to provide a more complete understanding of the factors and trends affecting the business than IFRS results alone. Because not all companies use identical calculations, the presentation of Adjusted EBITDA may not be comparable to other similarly titled measurements used by other companies. Readers should not consider Adjusted EBITDA in isolation or as a substitute for profit (loss) for the period as determined by IFRS, or as a substitute for an analysis of our Financial Statements.

UPATE ON OPERATIONS

Yield Growth has five wholly owned subsidiaries, Urban Juve, UJ Topicals, UJ Beverages Inc. (“UJ Beverages”), Yield Botanicals Inc. (“Yield Botanicals”) and Thrive Activations Inc.

Urban Juve

Urban Juve is an Ayurveda-inspired skin care and beauty brand that rejuvenates and nourishes from within: spirit to skin. Urban Juve’s key ingredient – cannabis sativa hemp root oil – combines with natural and pure essential oil-based formulations to create quality products that are now available online and are available at select retail stores across Canada.

As the Company’s flagship, Urban Juve is a bold brand rooted in the organic synthesis of ancient knowledge and modern techniques to create exceptional beauty and wellness solutions. Ayurvedic knowledge delineates three general categories or skin types, which Urban Juve has translated as Vitalize, Balance and Align, each with its own dedicated range of skin and body care formulations. Urban Juve has created unique formulas for more than 70 beauty and wellness products, has registered with Health Canada 35 products containing cannabis sativa hemp seed oil and hemp root oil and has filed 11 provisional patent applications in the United States.

The first eleven Phase I products have been launched through Urban Juve’s ecommerce website and over 70 retail stores across Canada have agree to carry the Urban Juve line.

Urban Juve is continuously developing new products and expects to launch over 20 additional products through 2019.  It has licensed the use of all of its formulas to UJ Topicals and the right to combine the formulas to create products containing cannabis.

UJ Topicals

Pursuant to its agreement with a licensed cannabis processing facility in Oregon, UJ Topicals’ products will be launching 9 cannabis products under the brand name “Wright and Well” in the Oregon legal cannabis market.  UJ Topicals expects to launch these first 9 products in Oregon in the second quarter of 2019.

UJ Beverages

UJ Beverages has completed the acquisition of eight wellness beverage formulas designed to be infused with CBD and THC and one capsule product intended to treat hangovers.
The formulas have been developed to offer various health benefits, including an energy boost, hangover treatment, brain function boost, anxiety reduction, improved immunity, toxin removal and reduced inflammation. The formulations were developed in India and are based on Ayurvedic medicine using botanicals, fruit extracts and spices.

Yield Botanicals

On March 12, 2019, Yield Botanicals entered an agreement with Vandenbosch Trading Company Ltd. to purchase a 10-acre property in Chilliwack, B.C., Canada. The purchase includes over 2.5 acres (approximately 100,000 square feet) of well-equipped and automated greenhouses, currently operating as an orchid flower grow and essential oil extraction business. The purchase price is $2.4 million subject to closing upon building inspection satisfactory to Yield Botanicals.

This strategic asset purchase will allow the Company to grow plants and build out extraction facilities in the existing infrastructure, while providing plenty of room for future expansion.  Owning a farm will give Yield Botanicals complete control of key proprietary ingredients for its products, including hemp root oil. The purchase will also empower the Company’s in-house research capabilities for growth and innovation.

The Company is also planning to optimize the farm’s current orchid growth and essential oil extraction to include new products. It plans to set up an additional extraction facility dedicated to hemp root oil—a key ingredient in Urban Juve products and in the cannabis topicals line launching in Oregon. Subject to acquiring the appropriate licenses, Yield Botanicals may also apply to cultivate industrial hemp for the purpose of hemp root oil extraction, and to carry out research and development to create cannabidiol from the parts of the hemp plant exempt from the Cannabis Act. The farm facilities will allow Yield Growth to grow herbs currently used in the Urban Juve product line, and extract essential oils on site, according to the Ayurveda philosophy.

Thrive

Thrive provides cutting-edge technology and marketing solutions to businesses.  Thrive was created to make technology solutions accessible to businesses looking for a competitive advantage. Thrive provides technology advisory, marketing and other business incubation services to other businesses.  Currently Thrive has two corporate clients.

About The Yield Growth Corp.

The Yield Growth Corp. is disrupting the global wellness market with hemp and cannabis-infused products that connect ancient healing with modern science. It is a vertically-integrated asset company with the leadership, financial position, and science-backed formulas to capitalize on the cannabis revolution. The Yield Growth management team has deep experience with relevant global brands including Johnson & Johnson, Procter & Gamble, M·A·C Cosmetics, Skechers, Best Buy, Aritzia, Coca-Cola, and Pepsi Corporation.  Yield Growth serves mainstream, luxury consumers who demand sophisticated wellness solutions.   Its flagship consumer brand, Urban Juve, has registered 35 products with Health Canada and has signed 70 retail locations to sell its products. Key ingredients in these products include Cannabis Sativa hemp seed oil and hemp root oil created using Urban Juve’s proprietary, patent-pending extraction technology. Urban Juve has also filed 11 provisional patents in the United States.  Through its subsidiaries, Yield Growth is commercializing over 70 wellness and cosmetic products and has multiple revenue streams including licensing, incubation services and product sales.

For more information about Yield Growth, visit www.yieldgrowth.com or follow @yieldgrowth on Instagram. Visit www.urbanjuve.com and #findyourjuve across social platforms to learn, engage and shop.

Investor Relations Contacts:

Penny Green, President & CEO
Kristina Pillon, Investor Relations

[email protected]

1-833-514-BOSS   1-833-514-2677
1-833-515-BOSS   1-833-515-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation.  Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements.  Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, intellectual property protection, and sale of, and demand for, Urban Juve, UJ Topicals, UJ Beverages and Yield Botanicals products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets.  Yield Growth cautions readers not to place undue reliance on forward-looking statements provided by Yield Growth, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Yield Growth expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/02a45234-e6e1-47a6-80cd-82e1197bb362

Yield Growth Corp. FISCAL YEAR ENDED NOVEMBER 30, 2018

FISCAL YEAR ENDED NOVEMBER 30, 2018

VANCOUVER, British Columbia, Feb. 01, 2019 (GLOBE NEWSWIRE) — The Yield Growth Corp. (CSE:BOSS)(OTCQB:BOSQF) (Frankfurt:YG3) is pleased to announce that the OTCQB Venture Market has approved the listing of the company’s shares on the OTCQB market under the ticker symbol “BOSQF” and that trading will begin at market open on February 1, 2019.  The company will also continue to trade on the Canadian Securities Exchange under ticker symbol “BOSS” and on the Frankfurt Exchange under the ticker symbol “YG3”.

“Trading on the OTCQB will help expand The Yield Growth Corp.’s presence in the U.S. with exposure to its equity market,” said Penny Green, President and CEO of The Yield Growth Corp. “This is an important milestone as we continue our track record of maximizing long term shareholder value. Further, we are pleased to make it easier for U.S. investors to buy our stock, especially now as we prepare to launch our products in the U.S.”

The OTCQB Venture is the premier marketplace for entrepreneurial and development stage U.S. and international companies that are committed to providing a high-quality trading and information experience for their US investors. To be eligible, companies must be current in their financial reporting, pass a minimum bid price test, and undergo an annual company verification and management certification process. The OTCQB Venture quality standards provide a strong baseline of transparency, as well as the technology and regulation to improve the information and trading experience for investors.

About The Yield Growth Corp.

The Yield Growth Corp. is dedicated to the rapid and sustainable growth of cannabis and wellness assets. Its directors and officers have experience at multi-billion dollar international companies including M.A.C Cosmetics, Aritzia, Skechers, Best Buy, Future Shop, Pepsi and Coca-Cola.  Its key assets are 100% owned subsidiaries Urban Juve Provisions Inc., UJ Topicals Inc., UJ Beverages Inc. and Thrive Activations Inc.  Through its subsidiaries it owns formulas to over 60 wellness products, including wellness formulas and beverages, has registered 29 products with Health Canada, has applied for 11 U.S. provisional patents and has established distribution and sales channels in Canada, the U.S. and Italy. It is currently selling products online and through retailers in Canada.

For more information about Yield Growth, visit www.yieldgrowth.com or follow @yieldgrowth on Instagram.  Visitwww.urbanjuve.com and #findyourjuve across social platforms to learn, engage and shop.

Investor Relations Contacts:

Penny Green, President & CEO

Kristina Pillon, Investor Relations

invest@yieldgrowth.com

1-833-514-BOSS   1-833-514-2677
1-833-515-BOSS   1-833-515-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation.  Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements.  Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, intellectual property protection, and sale of, and demand for, Urban Juve and UJ Topicals products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets.  Yield Growth cautions readers not to place undue reliance on forward-looking statements provided by Yield Growth, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially.  The forward-looking statements contained in this press release are made as of the date of this press release, and Yield Growth expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/dc57a7fa-6f0b-451f-8cd6-f65f9329c6f7

Yield Growth Now Listed on OTCQB

Yield Growth announces that it will commence trading on the OTCQB